| scholarly article | Q13442814 |
| P50 | author | Taha Abdel-Meguid | Q74607892 |
| P2860 | cites work | The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee | Q28138999 |
| Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction | Q34921103 | ||
| Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. | Q36373708 | ||
| Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results | Q36578115 | ||
| Botulinum toxin injection: a review of injection principles and protocols | Q36815354 | ||
| Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. | Q36995681 | ||
| Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. | Q37281713 | ||
| Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | Q46349100 | ||
| Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. | Q46539757 | ||
| Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. | Q53315918 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| Botulinum Toxin—New Mechanisms, New Therapeutic Directions? | Q61613765 | ||
| Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity | Q62626440 | ||
| Urge Incontinence can be a Disease of Bladder Sensors | Q68331032 | ||
| Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity | Q79400222 | ||
| Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux | Q79764800 | ||
| Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity | Q80812810 | ||
| Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity | Q81330318 | ||
| Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P304 | page(s) | 2423-2428 | |
| P577 | publication date | 2010-10-16 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial | |
| Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder—To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial | |||
| P478 | volume | 184 |
| Q39152548 | Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity: injections in detrusor, trigone and bladder neck or prostatic urethra, versus detrusor - only injections. |
| Q38181065 | Advances in the management of neurogenic detrusor overactivity in multiple sclerosis |
| Q37496473 | Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis |
| Q38076295 | Botulinum toxin for conditions of the female pelvis |
| Q36313192 | Botulinum toxin in neurogenic detrusor overactivity |
| Q33586589 | Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity |
| Q38675157 | Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity |
| Q39210488 | Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis |
| Q60923860 | Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis |
| Q38115204 | Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review |
| Q38184544 | Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice |
| Q26765052 | How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? |
| Q83046583 | Incontinence: Trigonal injection of botulinum toxin-A improves outcome |
| Q38780153 | Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment |
| Q58806215 | Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial |
| Q36115240 | Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study |
| Q97570183 | Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA |
| Q38097799 | Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity |
| Q38043442 | OnabotulinumtoxinA in the treatment of neurogenic bladder |
| Q36123446 | Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease |
| Q62626362 | Should we inject the trigone during botulinum toxin injection? |
| Q48328931 | The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. |
| Q26767310 | The role of botulinum toxin A in treating neurogenic bladder |
| Q60934967 | Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation |
| Q38248711 | Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events |
| Q37950864 | Updates in the management of the overactive bladder in patients with myelomeningocele |
Search more.